Contract development and manufacturing organisation (CDMO) Cobra Biologics and the Karolinska Institutet (KI) have been awarded €3 million in emergency funding to take a DNA vaccine for Covid-19 through phase I clinical trial testing.
With emerging biotechs playing a critical part in developing new drugs, Merck attempts to understand the interactions between parties when manufacturing monoclonal antibodies (mAbs).
Shabbir Mostafa, global key account director for Recipharm Inhalation Solutions, looks at the techniques to reduce time to market during inhalation drug development and manufacturing.
Charlie Johnson, CEO of biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps.
In this article with EPM, Dexter Tjoa, director of Corporate Strategy, discusses why outsourcing is fast becoming the most logical choice for companies who have delayed developing appropriate solutions and what benefits an experienced CPO can bring
In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019.
